Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

and we are excited to be moving our clinical program forward. We are very pleased that the MMRC sponsorship has made the rapid initiation of our Phase 2 trials possible and has enabled us to reach out to a larger group of myeloma patients. The thoughtful scientific expertise and collaborative effort of this group have helped speed development of new agents in the field of multiple myeloma," said Lori A. Kunkel, M.D., Chief Medical Officer of Proteolix, Inc.

About the Multiple Myeloma Research Consortium (MMRC)

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 13 Member Institutions: City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, Roswell Park Cancer Institute, Saint Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, and Washington University. In addition to these trials with Proteolix, the MMRC is supporting six other clinical trials exploring several investigative agents.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas- genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... DUBLIN , May 27, 2015 /PRNewswire/ ... ) has announced the addition of the  ... Testing Market"  report to their offering.  ... ,This comprehensive five-country report contains 500 pages, ... current suppliers and potential market entrants identify ...
(Date:5/27/2015)... May 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity ... patients suffer from a series of diverse complications arising ... the blood or tissues, which cause a rapidly progressing ... mortality rates near 50% depending on disease severity. The ... systems of the global marketplace, which for the purposes ...
(Date:5/27/2015)... PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market ... is an autoimmune disease that permanently destroys beta cells of ... longer produce insulin. Over the last 90 years, insulin therapy ... can be offered to a patient who is newly diagnosed ... of action - long-acting as well as short or rapid-acting ...
Breaking Medicine Technology:European Hemostasis Diagnostic Testing Market Strategies 2015 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4
... CITY, Calif., July 7 Relievant Medsystems, Inc., developer ... back pain, reported today that it has completed a ... led by Morgenthaler Ventures with existing investors Canaan Partners ... participating. The company also announced that Morgenthaler partner ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ... study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin ... published on-line in Diabetologia ... in the two treatment groups. This is the longest controlled ...
Cached Medicine Technology:Relievant Medsystems Announces Completion of $20 Million Financing 2Relievant Medsystems Announces Completion of $20 Million Financing 35-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 25-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 35-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 45-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 5
(Date:5/28/2015)... May 28, 2015 Although many people ... stuck with their slow metabolism for life, never being ... is not true. There are methods to jump start ... advertisements for low-carbohydrate, low-fat and no-fat foods, cleverly worded ... healthy, many times the foods contain hidden ingredients and ...
(Date:5/28/2015)... Texas (PRWEB) May 28, 2015 ... an updated version of his patient education website ... website redesign allows patients to readily access current ... erectile dysfunction treatment, male urinary incontinence, prostate cancer ... goal of this website is to educate patients ...
(Date:5/28/2015)... 28, 2015 SpendWell Health, an e-commerce ... has been named a “Cool Vendor” by Gartner in ... in Healthcare Payers, 2015 by Jeff Cribbs, Constance ... highlights innovative vendors, products and services in health care ... the health care payer market. , SpendWell’s solution ...
(Date:5/28/2015)... Sunshine Coast Health Center, one of ... at http://www.sunshinecoasthealthcentre.ca , is proud to announce ... the Toronto, Ontario, community. The company has a ... its online location information for Toronto residents. , ... we realize that addiction impacts family and friends," ...
(Date:5/28/2015)... The Cancer Solution: Taking Charge of ... researched and heartfelt book the Booksandauthor reviewer ever ... for writing what should be one of the most ... there is power in action and this book has both. ... to talk about and unfortunately many persons know little about ...
Breaking Medicine News(10 mins):Health News:As Part of their Comprehensive Weight Loss Program, Diet Doc Now Teaches Patients how to Identify Hidden Carbohydrates for Safe, Fast and Long Term Weight Loss Success 2Health News:As Part of their Comprehensive Weight Loss Program, Diet Doc Now Teaches Patients how to Identify Hidden Carbohydrates for Safe, Fast and Long Term Weight Loss Success 3Health News:As Part of their Comprehensive Weight Loss Program, Diet Doc Now Teaches Patients how to Identify Hidden Carbohydrates for Safe, Fast and Long Term Weight Loss Success 4Health News:Mark Allen MD, Dallas Urologist, Launches Updated Patient Education Website With a Focus on Prostate Cancer and Erectile Dysfunction Treatment 2Health News:SpendWell Named a “Cool Vendor” by Gartner 2Health News:SpendWell Named a “Cool Vendor” by Gartner 3Health News:SpendWell Named a “Cool Vendor” by Gartner 4Health News:Toronto Alcohol Treatment and Drug Rehab Local Information Page Updated, Announces Sunshine Coast Health Center 2Health News:Toronto Alcohol Treatment and Drug Rehab Local Information Page Updated, Announces Sunshine Coast Health Center 3Health News:Booksandauthor Cites The Cancer Solution as One of the Most Important Books to Read 2
... in teen, adult females, but not in men, study ... is associated with delayed childbearing in women, according to ... of alcohol dependence and their age when they had ... from two groups of Australian twins born between 1893-1964 ...
... Co., Inc. (OTC Bulletin Board: TYNP, TYNPE), a ... based in,Chengdu, China, today announced that the Company,s ... TYNPE due to the electronic eligibility,system error., ... Company expects the,stock symbol to trade under the ...
... Edward,G. Rendell today said Pennsylvania,s agricultural industry is ... system, underscoring the need,to secure the state,s energy ... Nearly 900 guests gathered to hear the ... at Ag Progress Days, Pennsylvania,s,largest outdoor agricultural exposition., ...
... (MGH) investigators have found that infusions of a particular ... from autoimmune attack in a mouse model. In ... , the team from the MGH Center for Engineering ... to control several immune system activities, allowed the regeneration ...
... Four Girls to My Beauty Camp ... this ... with the popular teenage Web site ELLEgirl.com to send four contest,winners later ... the new school year approaching, the goal of the camp is,to empower ...
... FALLS CHURCH, Va., Aug. 20 Scientists,physicians, ... Food,and Drug Administration,s (FDA) announcement that bisphenol A ... products including can,linings and baby bottles - is ... obesity, developmental problems, risk for heart,attack, and breast ...
Cached Medicine News:Health News:Women's Alcohol Use Tied to Delayed Childbearing 2Health News:Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction 2Health News:Pennsylvania Governor Rendell Highlights Renewable Energy, Health Care Reform at Ag Progress Days 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 2Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 4Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 5Health News:FDA Decision on BPA Outrages Health Advocates 2Health News:FDA Decision on BPA Outrages Health Advocates 3
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... DIFF CHEK-30 is a rapid ELISA ... 100% negative predictive value and 99% sensitivity. ... and cost-effectively screen out C. difficile negatives ... of samples - before culturing for the ...
Medicine Products: